If glycemic goals are not achieved, or if signs of overbasalization are evident (bedtime-to-morning glucose differential over 50 mg/dL, hypoglycemia, and significant glucose variability), progression to combination injectable therapy is generally recommended, considering GLP-1 receptor agonists with dual GIP and GLP-1 RA, or dual insulin therapy. This evidence concerns the gene GLP1R and Hypoglycemia.